3 Canadian Small-Cap Stocks to Buy Right Now

Given their favourable growth prospects, I expect these three Canadian small-cap stocks to deliver superior returns.

| More on:

Small-cap stocks have the potential to grow their financials at a high rate compared to mid-cap and large-cap stocks. So, these stocks can deliver superior returns. However, these stocks are highly susceptible to market volatility and are risky. So, investors with higher-risk-taking abilities and a longer investment horizon can invest in these stocks to earn superior returns.

Savaria

Savaria (TSX:SIS) had reported a solid second-quarter performance yesterday. Its revenue grew 111% to $178.6 million. The acquisition of Handicare and organic growth due to the recovery in economic activities drove the company’s top line. However, unfavourable currency translation offset some of the increases. Meanwhile, the company’s adjusted EBITDA also grew by 89.3% to $27.4 million, supported by strong top-line growth.

Meanwhile, the company’s addressable market is expanding amid a growing aging population and rising income levels. The company’s robust portfolio of products, increasing geographical footprint, and cross-selling opportunities from Handicare’s acquisition could boost its financials in the coming quarters. With its strong financial position, Savaria is well equipped to fund its growth initiatives. It also pays a monthly dividend of $0.04 per share, with its forward yield standing at 2.3%. So, Savaria would be an excellent buy for investors with over three years of an investment horizon.

WELL Health

Second on my list would be WELL Health Technologies (TSX:WELL), which has reported a solid second-quarter performance today. Its revenue grew 484% to $61.8 million, thanks to its acquisition of CRH Medical and strong growth of 432% in its virtual services revenue.

Along with top-line growth, the company’s adjusted EBITDA also rose. For the quarter, the company’s adjusted EBITDA came in at $11.9 million compared to an adjusted loss of $0.5 million in the previous year’s quarter. The accretive acquisition of CRH Medical and higher sales from its virtual services drove its adjusted EBITDA higher. Meanwhile, I expect the uptrend in the company’s financials to continue amid favourable market conditions and its continued acquisitions.

The company has acquired CRH, MyHealth, Intrahealth Systems, ExecHealth, and a 51% stake in Doctors Services Group in the second quarter. With these acquisitions, the company’s management expects its annualized revenue and adjusted EBITDA run rate have reached $400 million and $100 million, respectively. So, I believe the uptrend in WELL Health will continue.

HEXO

My final pick is Hexo (TSX:HEXO)(NYSE:HEXO), which trades over 66% lower from its January highs. Its weak third-quarter performance and lack of progress in cannabis legalization at the federal level in the U.S. have weighed on its stock price. However, amid increased legalization and rising cannabis usage for medical purposes, the cannabis market is expanding.

Amid the expansion of its addressable market, HEXO is looking to strengthen its competitive positioning by launching new products and raising THC content in its hash category. Its acquisitions could act as significant growth drivers. The company has acquired Zenabis while working on completing 48North Cannabis and Redecan deals.

These acquisitions could significantly expand its product offerings and strengthen its market share in the Canadian recreational cannabis space. Also, the synergies can deliver significant savings, thus improving HEXO’s margins. So, given its healthy growth prospects and a substantial discount on its stock price, I expect HEXO to deliver superior returns.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO Corp. and Savaria Corp. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Tech Stocks

data analyze research
Tech Stocks

Is BlackBerry (TSX:BB) a Buy in May 2025?

While its recent downturn might not look pretty, it might be the best opportunity to buy BlackBerry (TSX:BB) stock and…

Read more »

cloud computing
Tech Stocks

How I’d Allocate $14,000 in Tech Stocks in Today’s Market

These top tech stocks are perfect choices for investors looking for stable income, all from strong and growing industries.

Read more »

how to save money
Tech Stocks

If I Could Only Buy and Hold a Single Tech Stock, This Would Be it

Do you want long-term income? This tech stock is just getting started.

Read more »

Happy shoppers look at a cellphone.
Tech Stocks

Is Shopify (TSX:SHOP) a Screaming Buy Right Now?

Here’s why this e-commerce giant might be an excellent investment in the current market environment amid all the uncertainty.

Read more »

dividends can compound over time
Tech Stocks

Where I’d Put $10,000 in My TFSA for Long-Term Performance

Investors usually won't look to tech stocks for long-term investing, but in the case of this one they should!

Read more »

A microchip in a circuit board powers artificial intelligence.
Tech Stocks

Leading Canadian AI Contenders Every Tech Investor Should Consider

Smart tech investors might want to buy these two top Canadian AI stocks now and hold them for years to…

Read more »

A shopper makes purchases from an online store.
Tech Stocks

Shopify Stock Below $130: A Potential TFSA Accelerator for Tax-Free Capital Gains

Shopify stock has stabilized, and now it's looking like a strong top choice for investors.

Read more »

stocks climbing green bull market
Tech Stocks

Where I’d Invest $7,500 in These Top Undervalued Stocks With Potential for Appreciation

Investing in undervalued TSX stocks such as Electrovaya should help you deliver outsized gains in 2025 and beyond.

Read more »